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Neuropilin-1 Is Expressed by Endothelial
and Tumor Cells as an Isoform-Specific Receptor
for Vascular Endothelial Growth Factor
and subsequent tumor growth are inhibited in vivo by
antibodies directed against VEGF (Kim et al., 1993) by
soluble VEGF receptors (Kendall and Thomas, 1993) and
by expression of dominant-negative VEGF receptors
(Millauer et al., 1994). These properties have made the
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study of VEGF function relevant and significant for theHarvard Medical School
study of normal physiological angiogenesis and of an-Boston, Massachusetts 02115
giogenesis associated with abnormal cellular growth³Department of Biology
such as occurs in cancer.Technion
Structurally, VEGF is a 40±45Khomodimer with limitedIsrael Institute of Technology
sequence homology to the platelet-derived growth fac-Haifa 32000
tor (Keck et al., 1989; Tischer et al., 1989). Recently, aIsrael
number of structurally homologous VEGF family mem-
bers have been identified, including placenta-derived
growth factor (PlGF), VEGF-B, VEGF-C, and VEGF-Summary
related protein (reviewed in Klagsbrun and D'Amore,
1996). Human VEGF monomers exist as five differentVascular endothelial growth factor (VEGF), a major
isoforms of 121, 145, 165, 189, and 206 amino acidsregulator of angiogenesis, binds to two receptor tyro-
that are produced by alternative splicing from a singlesine kinases, KDR/Flk-1 and Flt-1. We now describe
gene containing eight exons (Tischer et al., 1991; Polt-the purification and the expression cloning from tumor
orak et al., 1997). VEGF121 and VEGF165 appear to becells of a third VEGF receptor, one that binds VEGF165
the most abundant of the isoforms. These two VEGFbut not VEGF121. This isoform-specific VEGF receptor
isoforms differ somewhat in their biological properties.(VEGF165R) is identical to human neuropilin-1, a recep-
For example, VEGF165 but not VEGF121 binds to cell sur-tor for the collapsin/semaphorin family that mediates
face heparan sulfate proteoglycan (HSPG), with the re-neuronal cell guidance. When coexpressed in cells with
sult that VEGF165 is partially retained by cells whileKDR, neuropilin-1 enhances the binding of VEGF165 to
VEGF121 is totally released (Houck et al., 1992). In addi-KDR and VEGF165-mediated chemotaxis. Conversely,
tion, VEGF165 is a more potent endothelial cell mitogeninhibition of VEGF165 binding to neuropilin-1 inhibits its
than VEGF121 (Keyt et al., 1996b; Soker et al., 1997).binding to KDR and its mitogenic activity for endothe-
VEGF activities are mediated by high affinity tyrosinelial cells. We propose that neuropilin-1 is a novel VEGF
kinase receptors associated with endothelial cells (EC).receptor that modulates VEGF binding to KDR and
Two such VEGF receptors have been identified: the 180subsequent bioactivity and therefore may regulate
kDa fms-like tyrosine kinase (Flt-1) (Shibuya et al., 1990;VEGF-induced angiogenesis.
de Vries et al., 1992) and the 200 kDa kinase insert
domain±containing receptor (KDR) (Terman et al., 1992)Introduction
and its murine homolog, Flk-1 (Millauer et al., 1993). KDR
binds VEGF and VEGF-C, whereas Flt-1 binds VEGFVascular endothelial growth factor (VEGF), also known
and PlGF. A third structurally related tyrosine kinaseas vascular permeability factor, is a prime regulator of
receptor, 180 kDa Flt-4, binds VEGF-C but not VEGFangiogenesis, vasculogenesis, and vascular permeabil-
(Joukov et al., 1996). KDR appears to be the major trans-ity (reviewed in Klagsbrun and Soker, 1993; Dvorak et
ducer of VEGF signals in EC that result in chemotaxis,al., 1995; Ferrara and Davis-Smith, 1997). The increased
mitogenicity, actin reorganization, and gross morpho-expression of VEGF has been correlated with vasculari-
logical changes in target cells (Waltenberger et al., 1994;zation of tissues, for example, during embryogenesis
Yoshida et al., 1996; Ferrara and Davis-Smith, 1997).(Breier et al., 1992; Millauer et al., 1993; Flamme et al.,
Targeted disruption of the KDR/Flk-1 gene in mice re-1995) and during the female reproductive cycle (Shweiki
sults in a defect in thedevelopment of EC and embryonicet al., 1993). Targeted disruption of even one allele of the
death by day 9.5 (Shalaby et al., 1995). Although Flt-1VEGF gene results in impaired blood vessel formation,
has a higher affinity for VEGF than KDR and is phosphor-growth retardation, and death by day 10.5 (Carmeliet et
ylated in response to VEGF, no mitogenic response isal., 1996; Ferrara et al., 1996). An important role for VEGF
generated (Waltenberger et al., 1994). Nevertheless,as a mediator of tumor angiogenesis is suggested by
Flt-1 appears to be an important mediator of angiogen-observations that high levels of VEGF are produced by
esis. It is localized to the endothelium in adult tissuevarious types of tumors (Dvorak et al., 1991; Plate et al.,
(Peters et al., 1993), and targeted disruption of this re-1992), capillaries are clustered along VEGF-producing
ceptor gene, while showing normal EC formation, resultstumor cells (Plate et al., 1992), and tumor angiogenesis
in impaired EC assembly into blood vessels and embry-
onic lethality (Fong et al., 1995).§To whom correspondence should be addressed.
VEGF has been typically considered to be an EC-‖ Present address: Department of Urology, Children's Hospital, Har-
specific growth factor (Keck et al., 1989; Leung et al.,vard Medical School, Boston, MA 02115.
1989; Plouet et al., 1989). However, there have been# Present address: The First Department of Medicine, Osaka Univer-
sity School of Medicine, Osaka, 565, Japan. several reports showing VEGF interactions with non-EC.
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For example, VEGF binds to Balb/C 3T3, HeLa, and
melanoma cells (Gitay-Goren et al., 1992; Enomoto et
al., 1994; Soker et al., 1996). It also stimulates the migra-
tion of monocytes and osteoblasts (Midy and Plouet,
1994; Barleon et al., 1996). Cell surface receptor cross-
linking experiments with 125I-VEGF have suggested that
additional VEGF receptors might exist that are neither
KDR nor Flt-1 (Gitay-Goren et al., 1996; Soker et al.,
1996; Omura et al., 1997). Recently, we identified and
characterized a 130±135 kDa VEGF receptor that is dif-
ferent fromKDR or Flt-1 (Soker et al., 1996). Interestingly,
this VEGF receptor is not only associated with EC but
with the cell surface of tumor cells as well, e.g., breast
carcinoma, prostate carcinoma, and melanoma. It has
a Kd of about 2±3 3 10210 M and is expressed in relatively
high copy number, 2.5 3 104 receptors/cell for EC and
1±2 3 105 receptors/cell for MDA-MB-231 (231) breast
carcinoma cells (Soker et al., 1996). A striking feature
of this receptor is that it binds VEGF165 but not VEGF121,
making it isoform-specific, and we thusnamed it VEGF165
receptor (VEGF165R). The structural difference between
VEGF165 and VEGF121 is the 44 amino acids encoded by
Figure 1. Purification and Expression Cloning of VEGF165R from 231VEGF exon 7. Recently, we demonstrated that a fusion
Cellsprotein containing the exon 7±encoded domain of VEGF165
(A) Purification. 125I-VEGF165 (5 ng/ml) was bound and cross-linkedbound VEGF165R directly and, furthermore, that it inhib-
to receptors on 231 cells and analyzed by SDS-PAGE and autoradi-ited 125I-VEGF165 binding to VEGF165R on EC and 231 cells ography (lane 1). VEGF165R was purified by Con A and VEGF165 affinity(Soker et al., 1996, 1997). Thus, the binding of VEGF165 chromatography and analyzed by SDS-PAGE and silver stain (lane
to VEGF165R occurrs via VEGF exon 7 in contrast to KDR 2). Two prominent bands were detected (arrows) and N-terminally
and Flt-1, which bind VEGF165 via VEGF exons 4 and 3, sequenced separately. Their N-terminal 18±amino acid sequences
are shown to the right of the arrows. The published N-terminalrespectively (Keyt et al., 1996a). The fusion protein also
sequences of human and mouse neuropilin (Kawakami et al., 1995;inhibited VEGF165-mediated EC proliferation (Soker et
He and Tessier-Lavigne, 1997) are shown below the VEGF165R se-al., 1997).
quences.
Given these results, we set out to purify and clone (B) Expression Cloning. Photomicrographs (dark-field illumination)
VEGF165R. In this report, we demonstrate by protein puri- of COS 7 cells binding 125I-VEGF165. 125I-VEGF165 was bound to trans-
fication and concomitant expression cloning that 231 fected COS 7 cells, which were then washed, fixed, and overlayed
with photographic emulsion that was developed as described incell±derived VEGF165R is identical to human neuropilin-1,
Experimental Procedures. Left, COS 7 cells were transfected with aa cell surface glycoprotein that has been previously as-
primary plasmid pool (number 55 of the 231 cell library) representingsociated with axonalguidance in the developing nervous
approximately 3 3 103 clones, and one COS 7 cell binding 125I-
system (Kawakami et al., 1995; Takagi et al., 1995) and VEGF165 in the first round of screening is shown. Right, several COS
that recently has been demonstrated to be the receptor 7 cells transfected with a single-positive cDNA clone (A2) binding
for the collapsin/semaphorin family of proteins (He and 125I-VEGF165 after the third round of screening.
Tessier-Lavigne, 1997; Kolodkin et al., 1997). A second
cDNA with 47% homology to neuropilin-1 (neuropilin-2)
does not form a ligand-receptor complex (Soker et al.,was also discovered by expression cloning. Transfec-
1996). The relatively high VEGF165R number and the lacktion of neuropilin-1 cDNA into cells lacking endogenous
of any detectable KDR or Flt-1 mRNA in 231 cells (dataVEGF receptors resulted in expression of a 130±140 kDa
not shown) suggested that these cells would be usefulreceptor that binds VEGF165 but not VEGF121. Further-
for VEGF165R purification. Preliminary characterizationmore, neuropilin-1 appears to act as a coreceptor that
indicated that VEGF165R was a glycoprotein. A combina-enhances VEGF165 binding to KDR and VEGF165 chemo-
tion of Con A Sepharose and VEGF165-Sepharose affinitytactic and mitogenic activity. We conclude that VEGF165R
chromatography was used for the purification of VEGF165Ris neuropilin-1 and that this receptor may have a novel
as described in Experimental Procedures. A prominentrole in VEGF-associated EC and tumor biology.
doublet with a molecular mass of about 130±135 kDa
was detected by SDS-PAGE and silver stain (Figure 1A,
lane 2). This size is consistent with the formation of aResults
165±175 kDa complex of 40±45 kDa VEGF165 bound to
receptors approximately 130±135 kDa in size (Figure 1A,Purification of VEGF165R
Cross-linking of 125I-VEGF165 to cell surface receptors of lane 1). The two bands were excised separately and
N-terminal amino acid sequencing was carried out (Fig-231 breast carcinoma cells results in formation of a
single 165±175 kDa labeled complex with VEGF165R (Fig- ure 1A, right). Both the upper and lower bands had
similar N-terminal amino acid sequences and showedure 1A, lane 1) (Soker et al., 1996). These cells have
about 1±2 3 105 VEGF165-binding sites/cell. In contrast high degrees of sequence homology to the predicted
amino acid sequences in the N-terminal regions ofto VEGF165, VEGF121 does not bind to the 231 cells and
Neuropilin is a VEGF Receptor
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Figure 2. The Deduced Amino Acid Se-
quence of Human neuropilin-1
The deduced 923±amino acid sequence of
the ORF of neuropilin-1 clone A2 (full insert
size of 6.5 kb) is shown. The putative signal
peptide sequence (amino acids 1±21) and the
putative transmembrane region (amino acids
860±883) are in boxes. The amino acid se-
quence obtained by N-terminal amino acid
sequencing (Figure 1A, amino acids 22±39)
is underlined. The arrow indicates where the
signal peptide has been cleaved and re-
moved based on comparison of the N-termi-
nal sequence of purified neuropilin-1 and the
cDNA sequence. The sequence of human
neuropilin-1 reported here differs from that
reported by He and Tessier-Lavigne (1997)
in that we find Lys26 rather than Glu26 and
Asp855 rather than Glu855. Lys26 and Asp855
are found, however, in mouse and rat neuro-
pilin-1 (Kawakami et al., 1995; He and Tes-
sier-Lavigne, 1997).
mouse (Kawakami et al., 1995) and human (He and Tes- with two hydrophobic regions representing putative sig-
nal peptide and transmembrane domains. Overall, thesier-Lavigne, 1997) neuroplilin-1.
sequence predicts ectodomain, transmembrane, and
cytoplasmic domains consistent with the structure of aExpression Cloning of VEGF165R
from 231 Cell-Derived mRNA cell surface receptor. The N-terminal sequence obtained
via protein purification as shown in Figure 1A is down-Concomitant with the purification, expression cloning
was used to clone VEGF165R. The details of these experi- stream of a 21±amino acid putative hydrophobic signal
peptide domain, thereby indicating directly where thements are described in Experimental Procedures. For
expression cloning, 231 cell mRNA was used to prepare signal peptide domain is cleaved and removed.
Sequence analysis of the one clone obtained by ex-a cDNA library of approximately 107 clones in a eukary-
otic expression plasmid. Pools of this library were pression cloning that had a different restriction enzyme
profile predicted an ORF of 931 amino acids with abouttransfected into COS-7 cells in separate wells, and indi-
vidual cells were screened for the ability to bind 125I- a 47% homology to neuropilin-1 (data not shown). This
human cDNA has a 93% sequence homology with ratVEGF165 as detected by autoradiography of monolayers
overlayed with photographic emulsion (Figure 1B, left). neuropilin-2 and is identical to the recently cloned hu-
man neuropilin-2 (Chen et al., 1997).After three rounds of subpooling and screening, seven
single-positive cDNA clones were obtained. Figure 1B
(right) shows binding of 125I-VEGF165 to COS-7 cells Expression of Neuropilin-1 in Adult Cell
Lines and Tissuestransfected with one of these single-positive clones
(clone A2). Reports of neuropilin-1 gene expression have been lim-
ited so far predominantly to the nervous system of theRestriction enzyme analysis revealed that six of the
seven single-positive clones had identical restriction di- developing embryo (Takagi et al., 1987, 1995; Kawakami
et al., 1995). Cell surface VEGF165R, however, is associ-gestion patterns, but one clone had a pattern that was
different (data not shown). Sequencing of one of the ated with nonneuronal adult cell types such as EC and
a variety of tumor-derived cells (Soker et al., 1996).identical cDNA clones, clone A2 (Figure 2), showed it
to be identical to a sequence derived from a human- Northern blot analysis was carried out to determine
whether cells that bind 125I-VEGF165 also synthesizedexpressed sequence tag data bank (dbEST). This se-
quence also showed a high percentage of homology to neuropilin-1 mRNA (Figure 3). neuropilin-1 mRNA tran-
scripts were expressed in human umbilical vein ECthe sequence of mouse neuropilin-1 (Kawakami et al.,
1995). After we had cloned human VEGF165R, two groups (HUVEC) (Figure 3A, lane 1). In tumor cell lines (Figure
3A, lanes 2±8), neuropilin-1 mRNA levels were highestreported the cloning of rat and human receptors for
semaphorin III and identified them to be neuropilin-1 in 231 and PC3 cells and to a lesser degree in LNCaP,
EP-mel, and RU-mel cells. There was little if any expres-(He and Tessier-Lavigne, 1997; Kolodkin et al., 1997).
The 231 cell±derived VEGF165R cDNA sequence is virtu- sion in MDA-MB-453 and WK-mel cells. The neuro-
pilin-1 gene expression patterns were consistent withally identical (see the Figure 2 legend for exceptions)
to the human neuropilin-1 sequence (He and Tessier- our previous results showing that HUVEC, 231, PC3,
LNCaP, EP-mel, and RU-mel cells bind 125I-VEGF165 toLavigne, 1997). Significantly, the predicted amino acid
sequence obtained byexpression cloning (Figure2) con- cell surface VEGF165R but that MDA-MB-453 and WK-
mel cells do not (Soker et al., 1996).firmed that VEGF165R was neuropilin-1 as was deter-
mined by N-terminal sequencing of purified receptor neuropilin-1 gene expression was analyzed also by
Northern blot in a variety of adult tissues in comparison(Figure 1A). The human neuropilin-1 cDNA sequence
predicts an open reading frame(ORF) of 923 amino acids to KDR gene expression (Figure 3B). neuropilin-1 mRNA
Cell
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Figure 4. Scatchard Analysis of VEGF165 Binding to Neuropilin-1
(A) Increasing amounts of 125I-VEGF165 (0.1±50 ng/ml) were added to
subconfluent cultures of PAE cells transfected with human neuropi-
lin-1 cDNA (PAE/NP-1 cells) in48-well dishes. No exogenous heparin
was added. After binding the cells were washed, lysed, and the cell-
associated radioactivity was determined using a g counter. Nonspe-
cific binding was determined by competition with a 200-fold excess
of unlabeled VEGF165.
(B) The binding data shown in (A) were analyzed by the method of
Scatchard, and a best fit plot was obtained with the Ligand program
(Munson and Rodbard, 1980). PAE/NP-1 cells express approxi-
Figure 3. Northern Blot Analysis of neuropilin-1 Expression
mately 4.5 3 104 VEGF165-binding sites per cell and bind 125I-VEGF165
(A) Human EC and tumor-derived cell lines. Total RNA samples with a Kd of 3 3 10210 M.
prepared from HUVEC and tumor-derived breast carcinoma, pros-
tate carcinoma, and melanoma cell lines as indicated were resolved
on a 1% agarose gel and blotted onto a GeneScreen nylon mem-
chosen for these expression studies because they ex-brane. The membrane was probed with 32P-labeled neuropilin-1
cDNA and exposed to X-ray film. Equal RNA loading was demon- press neither KDR, Flt-1, (Waltenberger et al., 1994),
strated by ethydium bromide staining of the gel prior to blotting. A nor VEGF165R. Stable cell lines synthesizing neuropilin-1
major species of neuropilin-1 mRNA of approximately 7 kb was (PAE/NP-1) were established, and 125I-VEGF165 bindingdetected in several cell lines.
experiments were carried out (Figure 4). 125I-VEGF165(B) Adult human tissues. A premade Northern blot membrane con-
binding to PAE/NP-1 cells increased in a dose-depen-taining multiple samples of human mRNA (Clontech) was probed
dent manner and reached saturation at approximatelywith 32P-labeled neuropilin-1 cDNA (top) and then stripped and re-
probed with 32P-labeled KDR cDNA (bottom). 30 ng/ml (Figure 4A). Scatchard analysis of VEGF165 bind-
ing revealed a single class of VEGF165-binding sites with
a Kd of approximately 3.2 3 10210 M and approximately
4.5 3 104 binding sites per cell (Figure 4B). Similar Kdlevels were relatively high in heart and placenta; more
values were obtained for several PAE/NP-1 clones gen-moderate in lung, liver, skeletal muscle, kidney, and
erated independently, although the receptor numberpancreas; and relatively low in adult brain. Interestingly,
varied from clone to clone (data not shown). The Kd ofprevious analysis of neuropilin-1 gene expression in
3.2 3 10210 M for the PAE/NP-1 cell lines is consistentmouse and chicken brain suggested that this gene was
with the 2±2.8 3 10210 M Kd values obtained for VEGF165Rexpressed primarily during embryonic development and
expressed naturally by HUVEC and 231 cells (Soker etwas greatly diminished after birth (Takagi et al., 1995;
al., 1996). The binding of 125I-VEGF165 to PAE/NP-1 cellsKawakami et al., 1995). The tissue distribution of KDR
was enhanced by 1 mg/ml heparin (data not shown),mRNA was similar to that of neuropilin-1, with the excep-
consistent with previous studies showing that heparintion that it was not expressed as highly in the heart.
enhances 125I-VEGF165 binding to VEGF165R on HUVECThese results indicate that neuropilin-1 is expressed
and 231 cells (Gitay-Goren et al., 1992; Soker et al.,widely in adult nonneuronal tissue, including tissues in
1996).which angiogenesis occurs such as heart and placenta.
Characterization of VEGF165 Binding to Neuropilin-1 Isoform-Specific Binding of VEGF to Cells
Expressing Neuropilin-1In order to characterize the binding properties of neu-
ropilin-1, porcine aortic endothelial (PAE) cells were VEGF165, but not VEGF121, binds to VEGF165R on HUVEC
and 231 cells (Gitay-Goren et al., 1996; Soker et al., 1996).transfected with neuropilin-1
Neuropilin is a VEGF Receptor
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Figure 5. Cross-linking of VEGF Isoforms to PAE Cells Expressing Neuropilin-1, KDR, or Both Receptors
Stable transfections. 125I-VEGF165 (5 ng/ml) (lanes 1±6) or 125I-VEGF121 (10 ng/ml) (lanes 7±10) were bound to subconfluent cultures of HUVEC
(lane 1), PC3 cells (lane 2), PAE cells (lanes 3 and 7), PAE cells transfected with human neuropilin-1 cDNA (PAE/NP-1) (lanes 4 and 8), PAE
cells transfected with KDR cDNA (PAE/KDR) (lanes 5 and 9), and PAE/KDR cells transfected with human neuropilin-1 cDNA (PAE/KDR/NP-1)
(lanes 6 and 10). At the end of a 2 hr incubation, each 125I-VEGF isoform was chemically cross-linked to the cell surface. The cells were lysed
and proteins were resolved by 6% SDS-PAGE. The polyacrylamide gel was dried and exposed to X-ray film. Solid arrows denote radiolabeled
complexes containing 125I-VEGF and KDR; open arrows denote radiolabeled complexes containing 125I-VEGF165 and neuropilin-1.
(B) Transient transfections. PAE/KDR cells were transfected with pCPhygro or pCPhyg-NP-1 plasmids as described in Experimental Procedures
and grown for 3 days in 6 cm dishes. 125I-VEGF165 (5 ng/ml) was bound and cross-linked to parental PAE/KDR cells (lane 1), PAE/KDR cells
transfected with vector control (V) (lane 2), PAE/KDR cells transfected with pCPhyg-NP-1 plasmids (NP-1) (lane 3), and HUVEC (lane 4). The
cells were lysed and proteins were resolved by 6% SDS-PAGE as (A). Solid and open arrows denote labeled complexes as in (A).
To ascertain whether cells transfected with neuropilin-1 KDR/NP-1 clones correlated positively with the levels
of neuropilin-1 expressed. Binding experiments werehad the same isoform binding specificity, PAE/NP-1
carried out to quantitate these results (data not shown).cells were incubated with 125I-VEGF165 or 125I-VEGF121 fol-
Increasing concentrations of 125I-VEGF165 were added tolowed by cross-linking (Figure 5A). 125I-VEGF165 did not
PAE/KDR and PAE/KDR/NP-1 cells. At 30 ng/ml, thebind to parental PAE cells (Figure 5A, lane 3) but did
levels of 125I-VEGF165 bound to PAE/KDR/NP-1 cells werebind to PAE/NP-1 cells via neuropilin-1 (Figure 5A, lane
about 6-fold higher than to PAE/KDR cells, consistent4). The radiolabeled complexes formed with neuropilin-1
with the cross-linking data shown in Figure 5. However,were similar in size to those formed in PC3 cells (Figure
accurate measurement of the individual affinities (Kds)5A, lane 2). On the other hand, 125I-VEGF121 did not bind
of VEGF165 binding to KDR and neuropilin-1 when theyto parental PAE (Figure 5A, lane 7) or to PAE/NP-1 cells
were coexpressed in PAE cells was difficult because(Figure 5A, lane 8). These results demonstrate that the
the Kds of KDR (Waltenberger et al., 1994; our results)VEGF isoform±specific binding that occurs with cells
and neuropilin-1 (Figure 4), when expressed indepen-expressing endogenous neuropilin-1 (VEGF165R) such
dently in PAE cells, are fairly similar.as HUVEC, 231, and PC3 cells can be replicated in cells
It could not be ruled out definitively that the enhancedtransfected with neuropilin-1 cDNA and support the
binding to KDR was possibly due to clonal selectionfinding that VEGF165R and neuropilin-1 are identical.
posttransfection. Therefore, parental PAE/KDR cells were
transfected with neuropilin-1 cDNA and 125I-VEGF165 wasCoexpression of Neuropilin-1 and KDR
bound and cross-linked to the cells 3 days later in orderModulates VEGF165 Binding to KDR to avoid selecting clones that might have shown diver-
To determine whether expression of neuropilin-1 had
sity in KDR expression (Figure 5B). A labeled 240 kDa
any effect on VEGF165 interactions with KDR, PAE cells complex containing KDR was formed in parental PAE/
that were previously transfected with KDR cDNA to pro- KDR cells (Figure 5B, lane 1) and in PAE/KDR cells
duce stable clones of PAE/KDR cells (Waltenberger et transfected with the expression vector alone (Figure 5B,
al., 1994) were transfected with neuropilin-1 cDNA, and lane 2). However, when 125I-VEGF165 was cross-linked
stable clones expressing both receptors (PAE/KDR/NP- to PAE/KDR cells expressing neuropilin-1 transiently, a
1) were obtained. These cells bound 125I-VEGF165 to KDR more intensely labeled 240 kDa complex, about four
(Figure 5A, lane 6, upper complex) and to neuropilin-1 times greater, was observed (Figure 5B, lane 3), com-
(Figure 5A, lane 6, lower complex) toyield a cross-linking pared to parental PAE/KDR cells (Figure 5B, lane 1)
profile similar to HUVEC (Figure 5A, lane 1). On the other and PAE/KDR cells transfected with expression vector
hand, PAE/KDR/NP-1 cells bound 125I-VEGF121 to form a (Figure 5B, lane 2). Taken together, the results shown
complex only with KDR (Figure 5A, lane 10), consistent in Figures 5A and 5B suggest that coexpression of KDR
with the inability of VEGF121 to bind to neuropilin-1. and neuropilin-1 genes in the same cell enhances the
It appeared that in cells coexpressing KDR and neu- ability of VEGF165 to bind to KDR.
ropilin-1 (Figure 5A, lane 6) the degree of 125I-VEGF165-
KDR 240 kDa complex formation was enhanced about Coexpression of Neuropilin-1 and KDR Enhances
4-fold compared to the parental PAE/KDR cells (Figure VEGF165 Chemotactic Activity
5A, lane 5). These results were reproducible, and the To determine whether neuropilin-1 expression modu-
lated VEGF165 bioactivity, PAE, PAE/NP-1, PAE/KDR,degree of 240 kDa complex formation in different PAE/
Cell
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Figure 6. VEGF-Induced Chemotaxis in PAE
Cells Expressing Neuropilin-1, KDR, or Both
Receptors
Chemotaxis of PAE cells (open circles), PAE
cells expressing neuropilin-1 (closed circles),
PAE cells expressing KDR (open boxes), and
PAE cells expressing both neuropilin-1 and
KDR (closed boxes) toward increasing con-
centrations of VEGF165 (A) or VEGF121 (B) was
measured in a Boyden chamber as described
in Experimental Procedures. Each point rep-
resents the mean cell number and standard
deviations of four independent wells.
and PAE/KDR/NP-1 cells were analyzed for theirchemo- to the levels seen in parental PAE/KDRcells not express-
ing neuropilin-1 (Figure 7A, lane 6 compared to lanetaxis toward gradients of VEGF165 or VEGF121 in a Boyden
chamber assay (Figure 6). There was no chemotaxis of 4). Similar inhibition of 125I-VEGF165 binding and cross-
linking to KDR by GST-Ex 718 was observed in HUVEC,parental PAE or PAE-NP-1 toward either VEGF isoform.
Both these cell types were viable, however, and mi- which express both KDR and neuropilin-1 (Soker et al.,
1997). Since the fusion protein does not bind to KDR,grated well toward 10% serum (data not shown). Both
VEGF165 (Figure 6A) and VEGF121 (Figure 6B) stimulated these results suggest that inhibiting the binding of 125I-
VEGF165 to neuropilin-1 directly inhibits its binding toPAE/KDR cell migration ina dose-response manner and,
to a similar extent, about 8-fold above control at 10 KDR indirectly.
To determine whether the inhibitory effects of GST-ng/ml VEGF. However, when PAE/KDR/NP-1 cells were
examined, a notable difference in chemotaxis was ob- Ex 718 on VEGF165 binding also affected VEGF-induced
mitogenicity, HUVEC were incubated with VEGF165 in theserved. VEGF165 at 10 ng/ml stimulated a 2.5-fold greater
migration of PAE/KDR/NP-1 cells compared to PAE/ presence or absence of GST-Ex 718 (Figure 7B). GST-
Ex 718 inhibited VEGF165-induced DNA synthesis byKDR cells, while VEGF121 did not induce any enhanced
migration. Checkerboard analysis (Yoshida et al., 1996; about 2- to 3-fold, confirming previous results (Soker et
al., 1997). GST alone did not affect HUVEC proliferation.Elenius et al., 1997) confirmed that the motility of the
cell types was due to chemotaxis (data not shown). It These results suggest that blocking VEGF165 access to
neuropilin-1 inhibits VEGF165 mitogenic activity.was concluded that coexpression of neuropilin-1 with
KDR not only results in increased VEGF165 binding to
KDR but in increased chemotaxis as well. Discussion
Neuropilin-1, a Mediator of Neuronal Guidance,A GST-VEGF Exon 718 Fusion Protein Inhibits
EGF165 Binding to VEGF Receptors Is an Isoform-Specific VEGF165 Receptor
Recently, we described a novel 130±135 kDa VEGF celland Mitogenicity for HUVEC
We have previously shown that 125I-VEGF165 binds to surface receptor that binds VEGF165 but not VEGF121 and
that we named, accordingly, VEGF165R (Soker et al.,VEGF165R through its exon 7±encoded domain and that
a GST fusion protein containing the peptide encoded 1996). We have now purified VEGF165R, expression
cloned its cDNA, and shown it to be identical to humanby VEGF exon 718 (GST-Ex 7 1 8) inhibits completely
the binding of 125I-VEGF165 to VEGF165R associated with neuropilin-1 (He and Tessier-Lavigne, 1997), a 130±140
kDa cell surface glycoprotein first identified in Xenopus231 cells and HUVEC (Soker et al., 1996, 1997). When
added to PAE/NP-1 cells, the fusion protein completely tadpole nervous tissue (Takagi et al., 1987). The evi-
dence that VEGF165R is identical to neuropilin-1 and thatinhibited binding to neuropilin-1 (Figure 7A, lane 2 com-
pared to lane 1). On the other hand, it did not inhibit neuropilin-1 serves as a receptor for VEGF165 is as fol-
lows: (i) Purification of VEGF165R protein from human125I-VEGF165 binding to KDR (Figure 7A, lane 4 compared
to lane 3). Thus, these results demonstrate that GST- MDA-MB-231 (231) cells using VEGF affinity yielded a
130±140 kDa doublet upon SDS-PAGE and silver stain.Ex 718 binds to neuropilin-1 but not to KDR. The effects
of GST-Ex 718 were different, however, in cells coex- N-terminal sequencing of both proteins yielded the
same N-terminal sequence of 18 amino acids that dem-pressing both neuropilin-1 and KDR. The degree of
125I-VEGF165 binding to KDR in PAE/KDR/NP-1 cells (Fig- onstrated a high degree of homology to mouse and
human neuropilin-1 (Kawakami et al., 1995; He and Tes-ure 7A, lane 5) was greater than to the parental PAE/
KDR cells (Figure 7A, lane 3), consistent with the results sier-Lavigne, 1997). The molecular mass of VEGF165R is
about 130±140 kDa, consistent with the size of neuropi-in Figure 5. In PAE/KDR/NP-1 cells, GST-Ex 718 inhib-
ited not only 125I-VEGF165 binding to neuropilin-1 com- lin-1. (ii) Expression cloning using a 231 cell cDNA library
resulted in isolation of several cDNA clones whose se-pletely, but, unexpectedly, it also inhibited binding to
KDR substantially (Figure 7A, lane 6 compared to lane quences were identical to that of human neuropilin-1
cDNA (He and Tessier-Lavigne, 1997). The combination5). In fact, in the presence of GST-Ex 718, binding of
125I-VEGF165 to KDR in PAE/KDR/NP-1 cells was reduced of purification and expression cloning has theadvantage
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Figure 7. Inhibition of 125I-VEGF165 Binding to
Neuropilin-1 Interferes with Its Binding to
KDR and Its Mitogenic Activity for HUVEC
(A) Inhibition of binding. 125I-VEGF165 (5 ng/ml)
was bound to subconfluent cultures of PAE
transfected with neuropilin-1 cDNA (PAE/
NP-1) (lanes 1 and 2), PAE cells transfected
with KDR (PAE/KDR) (lanes 3 and 4),and PAE/
KDR cells transfected with neuropilin-1 cDNA
(PAE/KDR/NP-1) (lanes 5 and 6) in 35 mm
dishes. The binding was carried out in the
presence (lanes 2, 4, and 6) or absence (lanes
1, 3, and 5) of 25 mg/ml GST-Ex 718. 125I-
VEGF165 was chemically cross-linked to the
cell surface. Cells were lysed and labeled pro-
teins were resolved by SDS-PAGE as in Fig-
ure 5. Solid and open arrows denote radiola-
beled complexes as in Figure 5.
(B) Inhibition of proliferation. HUVEC were cultured in 96-well dishes (5000 cells/well) with increasing concentrations of VEGF165 (open squares),
VEGF165 1 25 mg/ml of GST-Ex 718 (closed squares), or VEGF165 1 30 mg/ml GST alone (closed circles). After a 4 day incubation, incorporation
of 3H-thymidine into HUVEC was measured. The results represent the average count of three wells, and the standard deviations were
determined.
of allowing unambiguous identification of the neuro- studies demonstrating neuropilin-1 expression in capil-
lary EC in vivo in the embryonic mouse cardiovascularpilin-1 protein N terminus. (iii) Northern blot analysis of
neuropilin-1 gene expression was consistent with previ- system (Kitsukawa et al., 1995).
Neuropilin-1 has been identified recently as a receptorous 125I-VEGF165 cross-linking experiments (Soker et al.,
1996). (iv) Whenneuropilin-1 was expressed inPAE cells, that mediates the chemorepulsant activity of the col-
lapsin/semaphorins (collapsin-1/Sema III/Sem D), a largethe transfected cells were able to bind VEGF165 but not
VEGF121, consistent with the isoform specificity of bind- family of transmembrane and secreted glycoproteins
that function in repulsive growth cone and axon guid-ing previously shown for HUVEC and 231 cells (Soker
et al., 1996). Furthermore, the Kd of 125I-VEGF165 binding ance (Kolodkin et al., 1993, 1997; He and Tessier-Lavigne,
1997). The Kd of Sema III binding to neuropilin-1, 0.15±to PAE expressing neuropilin-1 was about 3 3 10210 M,
consistent with previous VEGF165R Kd binding values of 2 3.25 3 10210 M (He and Tessier-Lavigne, 1997; Kolodkin
et al., 1997) is similar to that of VEGF165 binding to neu-and 2.8 3 10210 M for HUVEC and 231 cells, respectively
(Soker et al., 1996). Taken together, these results show ropilin-1, which is about 2±3 3 10210 M. These results
indicate that two structurally different ligands with mark-that VEGF165R is identical to neuropilin-1.
In addition to the expression cloning of neuropilin-1 edly different biological activities, stimulation of angio-
genesis by VEGF and chemorepulsion of neuronal cellscDNA, another human cDNA clone was isolated whose
predicted amino acid sequence was 47% homologous by Sema III, bind to the same receptor and with similar
affinity. An interesting question is whether the two li-to that of neuropilin-1 and over 90% homologous to rat
neuropilin-2, which was recently cloned (Kolodkin et gands bind to the same site on neuropilin-1 or to differ-
ent sites. Neuropilin-1 has five discrete domains in itsal., 1997). Neuropilin-2 binds members of the collapsin/
semaphorin family selectively (Chen et al., 1997). Whether ectodomain, and it has been suggested that this diver-
sity of protein modules in neuropilin-1 is consistent withthis type of selectivity occurs for members of the VEGF
family is under investigation. the possibility of multiple binding ligands for neuropilin-1
(Takagi et al., 1991; Feiner et al., 1997; He and Tessier-The discovery that neuropilin-1 serves as a receptor
for VEGF165, an angiogenesis factor, is surprising since, Lavigne, 1997). Preliminary analysis does not indicate
any large degree of sequence homology between Semato date, neuropilin-1 has been considered to be essen-
tially a neuronal cell surface protein that plays a role in III and VEGF exon 7, which is responsible for VEGF
binding to neuropilin-1. However, there may be someaxon growth and guidance in the developing embryo
(Fujisawa et al., 1995; Kawakami et al., 1995). Our results three-dimensional structural similarities between the
two ligands. Since both neurons and blood vessels dis-are novel in showing that neuropilin-1 is also expressed
widely in human adult tissues. Northern blot analysis play branching and directional migration, it would be
interesting to determine whether VEGF165 displays anydemonstrates relatively high levels of neuropilin-1 mRNA
transcripts in nonneuronal human tissues such as heart, neuronal guidance activity and whether Sema III has
any EC chemorepulsant activity.placenta, lung, liver, skeletal muscle, kidney, and pan-
creas. Interestingly, there is very little relative neuro-
pilin-1 expression in adult brain, consistent with previ- A Role for Neuropilin-1 in Mediating VEGF165
Activity and Angiogenesisous studies in the mouse nervous system showing
greatly diminished neuropilin-1 expression after birth An important question is whether neuropilin-1 mediates
VEGF165 activity and, by extension, angiogenesis. Sev-(Kawakami et al., 1995). neuropilin-1 is also expressed
in a number of cultured nonneuronal cell lines including eral pieces of evidence presented here suggest that neu-
ropilin-1 regulates VEGF165/KDR interactions and VEGF165a variety of tumor-derived cells and EC. Expression of
neuropilin-1 by cultured EC is consistent with previous activity as follows: (i) Neuropilin-1 enhances the binding
Cell
742
of VEGF165 to KDR. When neuropilin-1 and KDR are coex- the chimeric mice showed hemorrhaging, mainly in the
pressed in EC, cross-linking and quantitative binding head and neck. These results are consistent with the
studies demonstrate that the binding of 125I-VEGF165 to possibility that ectopic overexpression of neuropilin-1
KDR in cells coexpressing neuropilin-1 is enhanced by results in inappropriate VEGF165 activity, thereby leading
4- to 6-fold compared to cells expressing KDR alone. It to aberrant angiogenesis. Furthermore, in a recent study
was not possible, however, to determine accurately the the embryos of transgenic mice targeted for disruption
effect of neuropilin-1 on KDR binding affinity due to the of the neuropilin-1 gene had severe abnormalities in the
similarities of the individual Kds of neuropilin-1 and KDR peripheral nervous system, but their death in utero at
in these cells. Enhanced binding can be demonstrated day 10.5±12.5 appeared to be due to anomalies in the
in stable clones coexpressing neuropilin-1 and KDR and cardiovascular system (Kitsukawa et al., 1997).
also in PAE/KDR cells transfected transiently with neu-
ropilin-1 cDNA where clonal selection does not take Neuropilin-1 Is Associated with
place. (ii) The chemotaxis of PAE coexpressing neuropi-
Tumor-Derived Cells
lin-1 and KDR toward a gradient of VEGF165 is enhanced The greatest degree of neuropilin-1 expression that weabout 2.5-fold compared to PAE expressing KDR alone.
have detected so far occurs in tumor-derived cells suchOn the other hand, there is no enhancement in the che-
as 231 breast carcinoma cells and PC3 prostate carci-motaxis of cells coexpressing the two receptors toward
noma cells, far more than occurs in HUVEC. The tumorVEGF121, consistent with the isoform-specific binding of
cells express abundant levels of neuropilin-1 mRNA andVEGF to neuropilin-1. PAE cells expressing neuropilin-1
about 200,000 VEGF165 receptors/cell (Soker et al., 1996).alone do not migrate in response togradients of VEGF165,
On the other hand, these tumor cells do not expresssuggesting that this receptor does not function by itself
KDR or Flt-1, so neuropilin-1 is the only VEGF receptorin mediating cell motility but acts rather as a coreceptor.
associated with these cells. The role of neuropilin-1 in(iii) Conversely, blocking VEGF165 access to neuropilin-
tumors in the absence of high affinity receptors is un-1 substantially inhibits VEGF165 binding to KDR and its
known. It may be that, besides the documented para-mitogenic activity for HUVEC. This result was achieved
crine effects of tumor cell-derived VEGF on stimulatingusing a GST fusion protein containing the 44±amino acid
EC, VEGF165 can affect tumor cells directly in an auto-exon 7 of VEGF, the domain responsible for VEGF165
crine manner. To date, we have not been able to showbinding to neuropilin-1, and the 6 amino acid exon 8,
VEGF165-induced phosphorylation of neuropilin-1 in tu-which facilitates production of the fusion protein (Soker
mor-derived cells, consistent with the lack of a consen-et al., 1996, 1997). GST-Ex 718 is not only a direct and
sus tyrosine kinase domain. Nevertheless, many othercomplete inhibitor of VEGF165 binding to neuropilin-1 in
cellular signaling mechanisms exist, and VEGF165 mightPAE/KDR/NP-1 cells, but it is also inhibits indirectly
have an effect on tumor cells by inducing some as yetVEGF165 binding to KDR down to the levels observed in
undetermined activity such as enhanced survival, differ-cells expressing KDR alone. The GST-Ex 718 protein
entiation, or motility. Another possibility is that tumoralso inhibits VEGF165 mitogenic activity for HUVEC by
cell neuropilin-1 has a storage and sequestration func-2- to 3-fold, confirming previous studies which showed
tion for VEGF165. The ability of VEGF165 but not VEGF121that VEGF165-induced HUVEC proliferation was inhibited
down to the level induced by VEGF121 (Soker et al., 1997). to bind to tumor cells via neuropilin-1 suggests that
The combination of experiments in which neuropilin-1 VEGF165 might have a broader spectrum of interaction
is either overexpressed or is inhibited suggest strongly and activities than does VEGF121, for example, with non-
that neuropilin-1 is functional in EC by serving as a endothelial cells.
coreceptor that enhances VEGF165 but not VEGF121 bind- A recent report has demonstrated that glioma cells
ing to KDR and subsequent bioactivity. The concept express a 190 kDa protein that binds VEGF165 efficiently
that dual receptors regulate growth factor binding and but not VEGF121 (Omura et al., 1997). No stimulation of
activity has been previously demonstrated for TGF-b, tyrosine phosphorylation of this receptor could be dem-
bFGF, and NGF (Yayon et al., 1991; Lopez-Casillas et onstrated upon binding of VEGF165. Whether the 190
al., 1993; Barbacid, 1995). Expression of betaglycan in kDa receptor is related to neuropilin-1 is not known
particular has been shown to increase TGF-b binding presently.
to its signaling receptor and to enhance cell respon- In summary, we have demonstrated by independent
siveness to TGF-b (Lopez-Casillas et al., 1993). At this purification and expression cloning methods that the
point, the possible effects of neuropilin-1 on mediating VEGF isoform±specific receptor VEGF165R is identical to
KDR signaling have not been determined. neuropilin-1, a neuronal cell surface protein previously
Compelling evidence suggesting that neuropilin-1 is identified as a receptor for the collapsin/semaphorin
involved in mediating angiogenesis comes from previ- family. Furthermore, expression of neuropilin-1 enhances
ous studies in other laboratories using transgenic mice the binding of VEGF165 to KDR and VEGF165 bioactivity.
(Kitsukawa et al., 1995). In the normal mouse embryo, Future studies are aimed at elucidating the mechanisms
neuropilin-1 is expressed in EC and in mesenchymal by which neuropilin-1 mediates VEGF165 bioactivity.
cells surrounding the EC. However, overexpression of
neuropilin-1 ectopically in transgenic mice resulted in
Experimental Proceduresembryonic lethality, and the mice died in utero no later
than on embryonic day 17.5. In these mice, the embryos Materials
possessed excess capillaries and blood vessels that Cell culture media, lipofectin, and lipofectamin were purchased from
were abnormal compared to normal counterparts. Di- Life Technologies. Human recombinant VEGF165 and VEGF121 were
produced in Sf-21 insect cells infected with recombinant baculoviruslated blood vessels were also observed and some of
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vectors as previously described (Cohen et al., 1992). GST VEGF size-fractionated on a 5%±20% potassium acetate gradient. DNA
fragments larger than 2 kb were ligated to an eukaryotic expressionexons 718 fusion protein was prepared in E. coli and purified as
previously described (Soker et al., 1996). Heparin, hygromycin B, plasmid, pcDNA3.1. The plasmid library was transfected into E. coli
to yield a primary library of approximately 1 3 107 individual clones.and protease inhibitors were purchased from Sigma (St. Louis, MO).
3H-thymidine, 125I-Sodium, 32P-dCTP, and GeneScreen-Plus hybrid- A portion of the transformed bacteria was divided into 240 pools,
each representing approximately 3 3 103 individual clones. DNAization transfer membrane were purchased from DuPont NEN (Bos-
ton, MA). Disuccinimidyl suberate (DSS) and IODO-BEADS were prepared from each pool was used to transfect COS-7 cells seeded
in 12-well dishes using the Lipofectin reagent according to the man-purchased from Pierce Chemical (Rockford, IL). Con A Sepharose
was purchased from Pharmacia LKB Biotechnology (Piscataway, ufacturer's instructions. Three days after transfection, the cells were
incubated on ice for 2 hr with 125I-VEGF165 (10 ng/ml) in the presenceNJ). RNAzol-B was purchased from TEL-TEST (Friendswood, TX).
Silver Stain kit and Trans-Blot PVDF membranes were purchased of 1 mg/ml heparin, washed, and fixed with 4% paraformaldehyde
from Bio-Rad Laboratories (Hercules, CA). Multiple-tissue Northern in PBS. 125I-VEGF165 binding to individual cells was detected by over-
blot membranes were purchased from Clontech (Palo Alto, CA). laying the monolayers with a photographic emulsion, NT-B2, and
PolyATract mRNA isolation kits were purchased from Promega developing the emulsion after 2 days as described (Gearing et al.,
(Madison, WI). DNA-labeling kits and molecularweight markerswere 1989). Seven positive DNA pools were identified, and DNA from one
purchased from Amersham (Arlington Heights, IL). pcDNA3.1 plas- of the positive pools was used to transform E. coli. The E. coli were
mid was purchased from Invitrogen (Carlsbad, CA), and pCPhygro subdivided into 50 separate pools and plated onto 50 LB ampicillin
plasmid, containing the CMV promoter and encoding hygromycin dishes, with each pool representing approximately 100 clones. DNA
B phosphorylase, was kindly provided by Dr. Urban Deutsch (Max made from these pools was transfected into COS-7 cells, which
Planck Institute, Bad Nauheim, Germany). Restriction endonucle- were screened for 125I-VEGF165 binding as described above. Twenty
ases and Ligase were purchased from New England Biolabs (Bev- positive pools were detected at this step, and their corresponding
erly, MA). NT-B2 photographic emulsion and X-ray film were pur- DNAs were used to transform E. coli. Each pool was plated onto
chased from the Eastman Kodak company (Rochester, NY). separate LB ampicillin dishes, and DNA was prepared from 96 indi-
vidual colonies and screened in a 96-well two-dimensional grid for
Cell Culture 125I-VEGF165 binding to tranfected COS-7 cells as described above.
HUVEC were obtained from American Type Culture Collection Seven single clones were identified as being positive at this step.
(ATCC) (Rockville, MD)and grown on gelatin-coated dishes inM-199 The seven positive plasmid clones were amplified, and their DNA
medium containing 20% fetal calf serum (FCS) and glutamine, peni- was analyzed by restriction enzyme digestion. Six clones showed
cillin, and streptomycin (GPS). Basic fibroblast growth factor (2 ng/ an identical digestion pattern of digest, and one was different. One
ml) was added to the culture medium every other day. Parental PAE clone from each group was submitted for automated DNA se-
cells and PAE cells expressing KDR (PAE/KDR) (Waltenberger et quencing.
al., 1994) were kindly provided by Dr. Lena Claesson-Welsh and
were grown in F12 medium containing 10% FCS and GPS. MDA-
Northern AnalysisMB-231 cells and MDA-MB-453 cells were obtained from ATCC
Total RNA was prepared from cells in culture using RNAzol ac-and grown in DMEM containing 10% FCS and GPS. The human
cording to the manufacturer's instructions. Samples of 20 mg RNAmelanoma cell lines RU-mel, EP-mel, and WK-mel were kindly pro-
were separated on a 1% formaldehyde-agarose gel and transferredvided by Dr. Randolf Byer (Boston University Medical School, Bos-
to a GeneScreen-Plus membrane. The membrane was hybridizedton, MA), and grown in DMEM containing 2% FCS, 8% calf serum,
with a 32P-labeled fragment of human neuropilin-1 cDNA corre-and GPS. Human metastatic prostate adenocarcinoma (LNCaP) and
sponding to nucleotides 63±454 in the ORF at 638C for 18 hr. Theprostate carcinoma (PC3) cells were kindly provided by Dr. Michael
membrane was washed and exposed to X-ray film for 18 hr. AFreeman (Children's Hospital, Boston, MA) and grown in RPMI 1640
commercially obtained multiple human adult tissue mRNA blotcontaining 5% FCS and GPS.
(Clontech, 2 mg/lane) was probed for human neuropilin-1 in a similar
manner. The multiple tissue blot was stripped by boiling in thePurification and Protein Sequencing
presence of 0.5% SDS and reprobed with a 32P-labeled fragment ofApproximately 5 3 108 MDA-MB-231 cells grown in 150 cm dishes
KDR cDNA corresponding to nucleotides 2841±3251 of the ORFwere washed with PBS containing 5 mM EDTA, scraped, and centri-
(Terman et al., 1992).fuged for 5 min at 500 3 g. The cell pellet was lysed with 150 ml of
20 mM HEPES (pH 8.0), 0.5% Triton X-100, and protease inhibitors
including 1 mM AEBSF, 5 mg/ml leupeptin, and 5 mg/ml aprotinin Transfection of PAE Cells
for 30 min on ice, and the lysate was centrifuged at 30,000 3 g for Human neuropilin-1 cDNA was digested with XhoI and XbaI restric-
30 min. MnCl2 and CaCl2 were added to the supernatant to obtain tion enzymes and subcloned into the corresponding sites of pCPhy-
a final concentration of 1 mM each. The lysate was absorbed onto gro to yield pCPhyg-NP-1. PAE and PAE/KDR cells were grown
a Con A Sepharose column (7 ml), and bound proteins were eluted in 6 cm dishes and transfected with 5 mg of pCPhyg-NP-1 using
with 15 ml 20 mM HEPES (pH 8.0), 0.2 M NaCl, 0.1% Triton X-100, Lipofectamine according to the manufacturer's instructions. Cells
and 1 M methyl-a-D-mannopyranoside at 0.2 ml/min. The elution were allowed to grow for an additional 48 hr, and the medium was
was repeated twice more at 30 min intervals. The Con A column replaced with fresh medium containing 200 mg/ml hygromycin B.
eluates were pooled and incubated for 12 hr at 48C with 0.5 ml of After 2 weeks, isolated colonies (5±10 3 103 cell/colony) were trans-
VEGF165-Sepharose beads containing about 150 mg VEGF165. VEGF165 ferred to separate wells of a 48-well dish and grown in the presence
was immobilized as described previously (Wilchek and Miron, 1982). of 200 mg/ml hygromycin B. Stable PAE cell clones expressing neu-
The VEGF165-Sepharose beads were washed with 50 ml of 20 mM ropilin-1 (PAE/NP-1) or coexpressing neuropilin-1 and KDR (PAE/
HEPES (pH 8.0), 0.2 M NaCl, and 0.1% Triton X-100 and then with KDR/NP-1) were screened for VEGF165 receptor expression by bind-25 ml of 20 mM HEPES (pH 8.0). The beads were boiled in SDS- ing and cross-linking of 125I-VEGF165. For transient transfection, PAE/PAGE buffer, and boundproteins were separated by 6% SDS-PAGE. KDR cells were transfected with neuropilin-1 as described above,
Proteins were transferred to a TransBlot PVDF membrane using a and after 3 days 125I-VEGF165 cross-linking analysis was carried out.semi-dry electric blotter (Hoefer Scientific), and the PVDF membrane
was stained with 0.1% Coomassie brilliant blue in 40% methanol.
Radioiodination of VEGF, Binding, and Chemical Cross-linkingThe two prominent proteins in a 130±140 kDa doublet were cut out
The radioiodination of VEGF165 and VEGF121 using IODO-BEADS wasseparately and N-terminally sequenced using an Applied Biosys-
carried out as previously described (Soker et al., 1997). The specifictems model 477A microsequenator, a service provided by Dr. Wil-
activity ranged from 40,000±100,000 cpm/ng protein. Binding andliam Lane of the Harvard Microchemistry Facility (Cambridge, MA).
cross-linking experiments using 125I-VEGF165 and 125I-VEGF121 were
performed as previously described in the presence of 1 mg/ml hepa-Expression Cloning and DNA Sequencing
rin (Gitay-Goren et al., 1992; Soker et al., 1996). VEGF binding wasComplementary DNA (cDNA) was synthesized from 5 mg 231 cell
mRNA. Double-stranded cDNA was ligated to EcoRI adaptors and quantitated by measuring the cell-associated radioactivity in a
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g-counter (Beckman, Gamma 5500). The counts represent the aver- Vascular permeability factor/vascular endothelial growth factor, mi-
crovascular hyperpermeability, and angiogenesis. Am. J. Path. 146,age of three wells. All experiments were repeated at least three
1029±1039.times and similar results were obtained. The results of the binding
experiments were analyzed by the method of Scatchard using the Elenius, K., Paul, S., Allison, G., Sun, J., and Klagsbrun, M. (1997).
LIGAND program (Munson and Rodbard, 1980). 125I-VEGF165 and 125I- Activation of HER4 by heparin-binding EGF-like growth factor stimu-
VEGF121 cross-linked complexes were resolved by 6% SDS/PAGE, lates chemotaxis but not proliferation. EMBO J. 16, 1268±1278.
and the gels were exposed to X-ray films that were subsequently Enomoto, T., Okamoto, T., and Sato, J.D. (1994). Vascular endothe-
scanned by using an IS-1000 digital imaging system (Alpha Innotech lial growth factor induces the disorganization of actin stress fibers
Corporation). accompanied by protein tyrosine phosphorylation and morphologi-
cal change in Balb/C3T3 cells. Biochem. Biophys. Res. Commun.
Proliferation and Chemotaxis Assays 202, 1716±1723.
VEGF-induced proliferation was measured by adding increasing Feiner, L., Koppel, A.M., Kobayashi, H., and Raper, J.A. (1997). Se-
amounts of VEGF to HUVEC in gelatin-coated 96-well dishes, and creted chick semaphorins bind recombinant neuropilin with similar
DNA synthesis was measured as described previously (Soker et al., affinities but bind different subsets of neurons in situ. Neuron 19,
1997). The preparation of the GST exon 718 fusion proteins and their 539±545.
use in HUVEC proliferation assays have been previously described
Ferrara,N., andDavis-Smith, T. (1997). The biology of vascular endo-(Soker et al., 1996, 1997). VEGF-induced chemotaxis was measured
thelial growth factor. Endocrine Rev. 18, 4±25.in a Boyden chamber as described previously (Yoshida et al., 1996;
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea,Elenius et al., 1997). Briefly, PAE, PAE/NP-1, PAE/KDR, and PAE/
K.S., Powell-Braxton, L., Hillan, K.J., and Moore, M.W. (1996). Het-KDR/NP-1 cells were added to wells in the upper chamber and
erozygous embryonic lethality induced by targeted inactivation ofincreasing amounts of VEGF isoforms were added to wells in the
the VEGF gene. Nature 380, 439±442.lower chamber. After a 4 hr incubation, the number of cells migrating
Flamme, I., Breier, G., and Risau, W. (1995). Vascular endothelialthrough the filter were counted. A checkerboard analysis was used
growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressedto ascertain that the migration was due to chemotaxis.
during vasculogenesis and vascular differentiation in the quail em-
bryo. Dev. Biol. 169, 699±712.Acknowledgments
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